-
Scientists from Johns Hopkins University have genetically engineered an experimental nanobody that targets alpha-synuclein protein clumps thought to be involved in the pathophysiology of Parkinson’s disease
Medical Mythbusting Commentary for August 9, 2022 Source:Parkinson’s research: Experimental nanobody targets toxic proteins Reference:α-Synuclein fibril-specific nanobody reduces prion-like α-synuclein spreading in mice